Ocular Therapeutix, Inc. OCUL
Set alert
6.97 USD -0.34 -4.65%
At close · Oct 30
7.03 +0.06 +0.86%
After hours · Oct 30, 6:43 PM ET
6.93 Day range 7.38
6.29 52-week range 16.11
- YTD
- -42.59%
- 1 year
- -41.03%
- Open
- 7.27
- Prev close
- 7.31
- Mkt cap
- 1.53B
- Vol
- 2.63M
- Avg vol
- 3.06M
- EPS
- -1.40
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.93
- High
- 7.38
- Forward P/E
- -4.71
- Beta
- 0.99
- Short ratio
- 7.60
- Inst. own
- 95.32%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 8.89
- 200-d avg
- 9.14
- 1y target
- 25.45
3M chart
Events in this range
- Aug 3, 2026Earnings: -0.35; estimate -0.39545; surprise 11.49%
- Sep 16, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Sep 16, 2026Rating: Chardan Capital · Buy → Buy
- Sep 29, 2026Rating: Needham · Buy → Buy
- Oct 2, 2026Rating: Chardan Capital · Buy → Buy
- Oct 12, 2026Rating: UBS · — → Buy
- Oct 19, 2026Rating: Needham · Buy → Buy
Signals (15)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 23, 2026 | 1 week ago |
| RSI: Oversold | Oct 19, 2026 | 1 week ago |
| RSI: Oversold | Sep 30, 2026 | 1 month ago |
| RSI: Oversold | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 16, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 10, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 9, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| RSI: Overbought | Aug 18, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
Key statistics
- Market cap
- 1.53B
- Enterprise value
- 1.09B
- Trailing P/E
- 0.00
- Forward P/E
- -4.71
- PEG ratio
- 0.00
- Price / sales
- 29.41
- Price / book
- 2.94
- EPS (TTM)
- -1.40
- Beta
- 0.99
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 52.05M
- Revenue growth
- 0.10%
- Free cash flow
- -159.25M
- Total cash
- 598.64M
- Total debt
- 79.38M
- Return on equity
- -72.99%
- Shares outstanding
- 219.62M
- Short % of float
- 15.46%
- 50-day average
- 8.89
- 200-day average
- 9.14
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 25.45 +265.2% upside
Now 6.97
- Target (low)
- 14.00
- Target (mean)
- 25.45
- Target (high)
- 34.00
Ratings (0m) 12 12 buy · 0 hold · 0 sell
- Strong buy4
- Buy8
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate -0.3548.
Financials — quick view
OCUL Revenue — quarterly 13.47M
OCUL Net income — quarterly -78.76M
OCUL EPS — quarterly -0.35
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -0.36348 | — | — | — |
| Aug 3, 2026 | Jun 30, 2026 | -0.39545 | -0.35 | +0.05 | +11.49% |
| May 5, 2026 | Mar 31, 2026 | -0.32 | -0.41 | -0.09 | -28.12% |
| Feb 5, 2026 | Dec 31, 2025 | -0.33 | -0.29 | +0.04 | +12.12% |
| Nov 4, 2025 | Sep 30, 2025 | -0.39 | -0.37 | +0.02 | +5.13% |
| Aug 5, 2025 | Jun 30, 2025 | -0.35 | -0.39 | -0.04 | -11.43% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2026 | Needham | reit | Buy | Buy |
| Oct 12, 2026 | UBS | init | — | Buy |
| Oct 2, 2026 | Chardan Capital | main | Buy | Buy |
| Sep 29, 2026 | Needham | reit | Buy | Buy |
| Sep 16, 2026 | Chardan Capital | main | Buy | Buy |
| Sep 16, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ocutx.com
News
- Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences
- Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity
- Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript
- Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win
- Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target
- UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14
- Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
- Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences
- Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target
Your note
Sign in to keep a note on OCUL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERMAN TODD | Officer | Sale | Oct 7, 2026 | 140,484 |
| DUGEL PRAVIN U | Chief Executive Officer | Stock Gift | Aug 24, 2026 | 0 |
| HEIER JEFFREY S. | Officer | Sale | Oct 1, 2026 | 307,457 |
| KAISER PETER KAZUO | Officer | Sale | Oct 1, 2026 | 254,388 |
| LINDSTROM RICHARD L | Director | Stock Award(Grant) | Jun 9, 2026 | 260,933 |
| MEYERS STEVE LAWRENCE | Officer | Stock Award(Grant) | Jan 1, 2026 | 217,628 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.96% | 32,844,043 | 228.92M | Jun 29, 2026 |
| Deep Track Capital, Lp | 8.96% | 19,686,282 | 137.21M | Jun 29, 2026 |
| Blackrock Inc. | 8.82% | 19,376,555 | 135.05M | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 5.71% | 12,540,000 | 87.40M | Jun 29, 2026 |
| Summer Road LLC | 5.56% | 12,208,296 | 85.09M | Jun 29, 2026 |
| Venrock Adviser, LLC | 4.71% | 10,346,926 | 72.12M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 4.42% | 9,704,363 | 67.64M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.01% | 6,616,995 | 46.12M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.53% | 5,562,722 | 38.77M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.23% | 2,700,674 | 18.82M | Aug 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 1.19% | 2,611,078 | 18.20M | Aug 30, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.03% | 2,252,224 | 15.70M | Jul 30, 2026 |